A clinical decision support system optimising adjuvant chemotherapy for colorectal cancers by integrating deep learning and pathological staging markers: a development and validation study.

Journal: The Lancet. Oncology
Published Date: Aug 11, 2022

Abstract

BACKGROUND: The DoMore-v1-CRC marker was recently developed using deep learning and conventional haematoxylin and eosin-stained tissue sections, and was observed to outperform established molecular and morphological markers of patient outcome after primary colorectal cancer resection. The aim of the present study was to develop a clinical decision support system based on DoMore-v1-CRC and pathological staging markers to facilitate individualised selection of adjuvant treatment.

Authors

  • Andreas Kleppe
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Ole-Johan Skrede
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Sepp De Raedt
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • Tarjei S Hveem
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Hanne A Askautrud
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.
  • Jørn E Jacobsen
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Research and Development, Vestfold Hospital Trust, Tønsberg, Norway.
  • David N Church
    Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK; National Institute of Health Research Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
  • Arild Nesbakken
    Department of Gastrointestinal Surgery, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway; KG Jebsen Colorectal Cancer Research Centre, Oslo, Norway.
  • Neil A Shepherd
    Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK.
  • Marco Novelli
    Dept of Pathology, University College London Hospital (UCLH), London, United Kingdom.
  • Rachel Kerr
    Department of Oncology, University of Oxford, Oxford, UK.
  • Knut Liestøl
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway.
  • David J Kerr
    Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK.
  • Håvard E Danielsen
    Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway; Department of Informatics, University of Oslo, Oslo, Norway; Nuffield Division of Clinical Laboratory Sciences, University of Oxford, Oxford, UK. Electronic address: hdaniels@labmed.uio.no.

Keywords

External Resources

Popular Topics
Recent Journals